title: NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice.
abstract: The anxiolytic-like activity of magnesium in mice during the elevated plus maze (EPM) has been demonstrated previously. In the present study, we examined the involvement of NMDA/glutamate receptor ligands on the magnesium effect on the EPM. We demonstrated that low, ineffective doses of NMDA antagonists (the competitive NMDA antagonist CGP 37849, 0.3 mg/kg; an antagonist of the glycineB sites, L-701,324, 1 mg/kg; a partial agonist of the glycineB sites, D-cycloserine, 2.5 mg/kg; and the non-competitive NMDA antagonist MK-801, 0.05 mg/kg) administered together with an ineffective dose of magnesium (10 mg/kg) evoked a significant increase in the percentage of time spent in the open arm of the maze (an index of anxiety). Moreover, magnesium-induced anxiolytic-like activity (20 mg/kg) was antagonized by D-serine (100 nmol/mouse), an agonist of glycineB site of the NMDA receptor complex. The present study demonstrates the involvement of the NMDA/glutamate pathway in the magnesium anxiolytic-like activity in the EPM in mice, and that this activity particularly involves the glycineB sites.
authors.affiliation: Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Staszica 4, PL 20-081 Lublin, Poland. ewa.poleszak@am.lublin.pl
authors.forename: Ewa
authors.initials: E
authors.lastname: Poleszak
authors.forename: Piotr
authors.initials: P
authors.lastname: Wlaź
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wróbel
authors.forename: Sylwia
authors.initials: S
authors.lastname: Fidecka
authors.forename: Gabriel
authors.initials: G
authors.lastname: Nowak
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents; D000963:Antimetabolites / Q000494:pharmacology; D001224:Aspartic Acid / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D003523:Cycloserine / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018684:Glycine Agents / Q000494:pharmacology; D008297:Male; D051379:Mice; D015363:Quinolones / Q000494:pharmacology; D017470:Receptors, Glutamate / Q000187:drug effects*; D018009:Receptors, Glycine / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects*
chemical_list: D014151:Anti-Anxiety Agents; D000963:Antimetabolites; D018691:Excitatory Amino Acid Antagonists; D018684:Glycine Agents; D015363:Quinolones; D017470:Receptors, Glutamate; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C064539:2-amino-4-methyl-5-phosphono-3-pentenoic acid; D001224:Aspartic Acid; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate; D003523:Cycloserine; C094635:L 701324